OTC fever blister treatments
Are not generally recognized as safe and effective and are misbranded, FDA states in final rule published June 30. "There is a lack of adequate data," FDA says, to establish the safety and efficacy of the ingredients lysine, Lactobacillus acidophilus and Lactobacillus bulgaricus, or any other oral ingredients to treat fever blisters and cold sores. Rule takes effect Dec. 20.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth